Research over the last decade has extended the prevailing view of mitochondria to include functions well beyond the critical bioenergetics role in supplying ATP. It is now recognized that mitochondria play a crucial role in cell signaling events, inter-organelle communication, aging, many diseases, cell proliferation and cell death.
Mitochondria, the organelles long thought to serve only as cellular energy generators, are now known to function well beyond this critical bioenergetic role. Mitochondria play a crucial role in modulation of cell redox status, osmotic regulation, pH control, calcium homeostasis and cell regulatory and signaling events, responses of cells to a multiplicity of physiological and genetic stresses, inter-organelle communication, and cell proliferation, and they also act as a center of apoptotic regulation. The mitochondrion is comprised of about 1000 different proteins with tissue-specific features. One of these proteins, controlling both cell life and death, is the voltage-dependent anion channel (VDAC).
While the inner mitochondrial membrane (IMM) contains numerous α-helical transport proteins [1] , the major transport protein in the outer mitochondrial membrane (OMM) is the mitochondrial β-strand VDAC, also called porin. The OMM provides a barrier between the mitochondrial innermembrane matrix and the cell cytoplasm, and in this membrane, VDAC mediates the complex interactions between mitochondria and other parts of the cell by transporting anions, cations, ATP, Ca 2+ and metabolites. Thus, VDAC plays an important role in coordination of communication between mitochondria and cytosol. An essential aspect of this management is the transient formation of complexes of VDAC with other proteins.
*Address corresponding to this author at the Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel; Fax: 972-8-6472992; E-mail: vardasb@bgu.ac.il During transduction of an apoptotic signal into the cell, an alteration in the mitochondrial membrane permeability occurs, causing the release of apoptogenic proteins, including cytochrome c, AIF, caspase 8 and Smac. These proteins participate in the complex processes resulting in activation of proteases and nucleases leading to protein and DNA degradation, and finally cell death. Over the past few years, several hypotheses and potential mechanisms have been forwarded for and against a role for VDAC in OMM permeability and the subsequent release of apoptosis-promoting proteins. Continued research into the mechanisms of mitochondria-mediated apoptotic cell death, coupled with further characterization of the released molecules, will no doubt offer new and promising targets for chemotherapeutic intervention in a host of pathologies.
Several recent reviews have focused on VDAC as an essential player in apoptosis [2] ; on new functions of VDAC [3] ; on the function of complexes of VDAC and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis [4] ; on the modulation of VDAC and its contribution to the mitochondrial role in cell life and death [5] ; on VDAC structure [6] ; and on the location and function of VDAC in sarcoplasmic reticulum membranes [7] . This review outlines current knowledge related to the role of VDAC in coordination of communication between mitochondria and cytosol and in the regulation of apoptotic cell death. Specifically, we highlight numerous results suggesting possible therapeutic applications based on modulation of VDAC activity or expression.
VDAC STRUCTURE, ISOFORMS AND CHANNEL ACTIVITY

VDAC Molecular Structure and Membrane Topology
Since the first report on porins isolated from eukaryotes [8] , they have frequently been called voltage-dependent anion-selective channels (VDAC) on the basis of their electrophysiological characteristics. The VDACs are pore-forming proteins found in the outer mitochondrial membranes of all eukaryotes (e.g., paramecia, yeast, fungi, plants, and mammals (reviewed in [9, 10] ). Structural and electrophysiological properties are conserved in VDAC from different sources [3, 6, 11, 12] .
Mammalian VDAC is a 31-kDa protein comprised of one polypeptide having stretches of alternating hydrophobic and hydrophilic amino acids that form a transmembrane β-barrel composed of a single α-helix at the N-terminus, and several transmembrane amphipathic β-strands; the α-helix at the Nterminus protrudes outside [13] , crosses the membrane [6] or interacts with the membrane or membrane proteins [14] . Computer modeling of VDAC's primary amino acid sequence has led to the development of models showing the transmembrane organization, consisting of a single α-helix and 13-, 16-or 19-transbilayer β-strands [6, 13, 14] . These β-strands are connected by several peptide loops of different sizes on both sides of the membrane that serve as potential protein interacting sites [6, [15] [16] [17] (Fig. 1A) .
It is accepted that monomeric VDAC serves as the functional channel [18, 19] . However, evidence consistent with oligomerization of purified VDAC from rat liver or Neurospora crassa, and in yeast OMM suggests that VDAC can form dimers, and possibly tetramers [20] [21] [22] [23] . Using rat liver ( [24] and Fig. 1B ), brain mitochondria [25] or recombinant human VDAC [26] , the existence of VDAC dimers to tetramers has been reported. The possibility has recently been proposed that VDAC oligomerization functions in mitochondria-mediated apoptosis [24, 26] .
Detailed structural analyses of VDAC will depend on determining the 3-D structure of VDAC, but this has been impeded by difficulties in growing crystals, thus frustrating our ability to explore VDAC structure-function relationships.
VDAC Conductance, Voltage Dependence and Ion Selectivity
VDAC has been purified using various procedures and detergents (reviewed in [5] ), and characterized by reconstitution into a planar lipid bilayer (PLB). Bilayer reconstituted VDAC forms a voltage-dependent channel and possesses multiple conformational states, resulting in varying selectivity and permeabilities [3, 5, 6, 10] . Depending on the substate, VDAC pore diameter has been estimated to be between 1.8-3 nm [10, 27] . VDAC shows a symmetrical voltagedependent conductance [10, 11] , depending on the transmembrane potential (Fig. 2) . The channel has its highest conductance states at low potentials (4 nS at 1 M KCl), with preference for anions such as phosphate, chloride, adenine nucleotides and other metabolites (as most are anionic). At higher positive or negative potentials (>30-60mV), the pore size is reduced to 2 nm and VDAC is at sub-conductance states, with 50-60% reduced conductance; the selectivity shifts to small cations and the channel becomes virtually impermeable to ATP and ADP [10, 11, [28] [29] [30] [31] [32] [33] . As a voltagegated channel, VDAC must possess a voltage sensor that responds to changes in transmembrane voltage. It is believed that VDAC channels have two separate gating processes: one at positive transmembrane potentials and the other at nega- A. Proposed VDAC topology includes a transmembrane organization of a single α-helix and 13 transbilayer β-strands [6] . Glutamate 72 is indicated by an arrow.
B. Mitochondria (1 mg/ml) were incubated for 10 min at 30 o C in 10 mM Tricine, pH 8.3 with DFDNB (50 µM), EGS (100 µM), or DSP (200 µM). Samples were subjected to SDS-PAGE (10 % acrylamide), stained with Coomassie blue (CBB) or subjected to Western blot analysis using anti-VDAC antibodies (Blot). VDAC monomer, dimer, trimer and tetramer are indicated. The positions of molecular weight protein standards are indicated.
tive potentials, where VDAC closure is associated with motion of the positively-charged voltage sensor [19, 34] . It has been postulated that a positively charged loop moves out of the channel [34] , but it is also possible that negative charges move into the mouth of the channel, as has been observed for bacterial porins [35] . Thus, the molecular nature of the VDAC gating mechanism is not yet resolved.
The Physiological Significance of VDAC Voltage Gating
As indicated above (also see Fig. 2 ), at high positive or negative membrane potentials, VDAC is in the low conductance, cation-selective state that is not permeable to ATP, ADP or other negatively charged small molecules. Thus, voltage changes can control the fluxes of ions and metabolites in and out of the mitochondria. The physiological significance of the voltage dependence of VDAC is not clear and has been quite controversial. For years, it was assumed that the OMM is freely permeable to various ions and metabolites due to VDAC and thus no membrane potential could be maintained. If there is no significant membrane potential across the OMM, one would not expect the modulation of VDAC conductance and selectivity by voltage changes. After it was found that VDAC is a controlled channel and that the OMM limits transport in and out of the mitochondria, a variety of ways to generate a membrane potential were proposed. For example, it was proposed that a potential difference exists across the OMM as a natural consequence of the presence of charged macromolecules in the intermembrane space and the cytosol [36] . Another proposal takes into account the motion of charged substrates associated with mitochondrial metabolism [37] . Differential permeability of VDAC to metabolites could also result in a transmembrane potential. It has been postulated that VDAC is voltage regulated in the contact sites where the potential across the inner membrane would somehow spill over by capacitive coupling to the outer membrane due to the proximity of the two membranes [30] . While this specific proposal is rather unlikely, metabolic cycling associated with ATP, ADP, and Pi translocation could couple potential generation in the inner membrane to the formation of a potential in the outer membrane (for details see [37] ). The demonstration of a membrane potential across the OMM and its physiological significance await additional studies.
VDAC Isoforms and Functions
In human, rat and mouse, three different VDAC genes encoding distinctly expressed isoforms have been reported [12, [38] [39] [40] . VDAC isoforms appear to have specialized functions since the more complex the multicellular organism, the more VDAC isoforms it possesses. Neurospora crassa have only one form of VDAC, Saccharomyces cerevisiae have two, and mice and humans have three [12, 41] . In yeast, only VDAC1 (and not VDAC2) forms channels when reconstituted into phospholipid membranes, and seems to provide the major pathway for NADH transport across the OMM [41] [42] [43] [44] . Moreover, when type I VDAC is deleted, type II cannot replace it, but instead, TOM 40, a pore for mitochondrial precursor peptides, is over-expressed [45] . Human and mouse VDACs have more than 85% similarity at the level of amino acids, but they have less than 30% sequence identity with yeast VDAC, although they share similar channel characteristics. Human and mouse VDAC1 and VDAC2 isoforms show channel forming activity in vitro and can complement the yeast VDAC1 deficiency [39] , while VDAC3 can only partially complement this defect [12] .
The three genes that encode distinct isoforms of mouse VDAC, VDACs 1-3, have been characterized [12] . Each isoform is 65-70% identical to the other isoforms [46] . Phylogenetic analysis indicates that VDAC3 is the more primordial of the vertebrate VDAC genes, suggesting that if the VDAC purified from sheep liver mitochondria (SLM) (A) was reconstituted into a PLB. Currents through VDAC in response to a voltage step from 0 to -10 mV or to -60 mV were recorded. The dashed lines indicate current-zero level (B). Multi-channel recordings of the VDAC average steady-state conductance as a function of voltage (C). Relative conductance was determined as the ratio of conductance at a given voltage (G) to maximal conductance (Go). multiple isoforms arose from a gene duplication and divergence event, VDAC3 diverged from the primordial VDAC first, with VDAC1 and VDAC2 arising more recently [47] . Mammalian VDAC isoforms are expressed in a wide variety of tissues and are expressed at high levels in heart, kidney, brain, and skeletal muscle. VDAC1 may represent the predominant form expressed in the tissues that have been tested [48] . Both VDAC1 and VDAC2 are ubiquitously expressed, while VDAC3 has a more restricted organ distribution [12, 49, 50] . However, the tissue specific distributions and intracellular localization of the different VDAC isoforms are not well established. VDAC isoforms appear to display different physiological functions [51] . Some differences in voltagedependent gating and other properties of the VDAC isoforms have been reported [46] , and binding of hexokinase (HK) appears to be a specific feature of VDAC1 [39] . However, the possible relationship between such differences and distinct physiological roles for these isoforms remains to be defined. One difference in function which has been found is that VDAC1 is connected with apoptosis through its interaction with different proteins and factors [5, 6, 52] , while VDAC2 has been associated with anti-apoptotic activity [51] .
In mice, knock-out of VDAC1 and VDAC2 reduces respiratory capacity [53] , knockout of VDAC3 causes male sterility, and the lack of both VDAC1 and VDAC3 causes growth retardation [54] . VDAC1-and VDAC3-knockout mice show deficits in learning behavior and synaptic plasticity [55] . The effects of selective deficit in one or the other of these isoforms are not equivalent, implying that VDAC1 and VDAC3 play somewhat different roles in these cerebral functions, although those roles are still undefined. Airway epithelia from mice knocked-out for VDAC1 exhibit slower regulatory volume decrease and reduced ATP release in response to stimuli, suggesting the involvement of plasmalemmal VDAC1, a splice variant of mitochondrial VDAC1, in these functions [56] . Cells deficient in VDAC2, but not cells lacking the more abundant VDAC1, exhibit enhanced BAK oligomerization and are more susceptible to apoptotic death [51] , as supported by recent results suggesting VDAC2 as a critical inhibitor of Bak-mediated apoptotic responses [57] .
Thus, by gene targeting, it has been demonstrated that each VDAC isoform, individually, is dispensable, yet no cell line lacking more than one VDAC could be generated [53] . Recently, siRNA-mediated VDAC1 knock-down cells were found to proliferate extremely slowly in comparison to normal VDAC expressing cells, indicating the necessity of VDAC1 for cell life [58] .
Extra-Mitochondrial Localization of VDAC
Various studies have revealed that VDAC is also localized to cell compartments other than mitochondria (for review see [7] ). VDAC has been found in the plasma membrane family. Caveolae and caveolae-like domains were shown to contain VDAC [59] . The presence of VDAC in the SR of amphibian and of mammalian skeletal muscles has also been demonstrated [7] as well as VDAC in endoplasmic reticulum (ER) of rat cerebellum [25] . The extra-membranous localization of VDAC type 2 and type 3 in the bovine outer dense fibers, a cytoskeletal component of the sperm flagellum, has been reported [60] . In spite of this accumulating evidence, VDAC localization in extra-mitochondrial membranes has been questioned by Yu et al. [61] . The exact function of extra-mitochondrial VDAC is as yet unknown. Several possible functions have been proposed, including serving as part of the outwardly rectifying depolarization-induced chloride (ORDIC) channel complex [14] , involvement in volume regulation in brain tissue [62] , and contributing to ATP release and cell volume regulation [56] . The possible functions of VDAC in SR/ER include providing a pathway for transport of Ca 2+ , nucleotides and other metabolites across the membrane, and involvement in apoptosis. The participation of VDAC in supramolecular complexes and intracellular communication, including calcium signal delivery between the ER and mitochondria, has also been proposed (see [7] ).
VDAC AS A GATEKEEPER IN MITOCHONDRIA-MEDIATED APOPTOSIS
Mitochondria and Apoptosis
Apoptosis, or programmed cell death, is a genetically regulated process that plays an important role in tissue homeostasis and development in multicellular metazoans. Defects in regulation of apoptosis are often associated with diseases, such as neuronal degenerative diseases, tumorigenesis, autoimmune disorders, and viral infections [63, 64] . Mitochondria play an important role in the regulation of programmed cell death via release of pro-apoptotic agents and/or disruption of cellular energy metabolism [65] [66] [67] [68] . The pro-apoptotic signal can be generated inside the mitochondria, for example, by increased Ca 2+ and/or free radicals (ROS) concentrations but it can also be initiated from outside by pro-apoptotic proteins such as t-Bid and Bax. In this way, mitochondrial apoptosis induction is used to amplify the extra-mitochondrial pro-apoptotic message coming from FAS receptors or increased p53. Mitochondria-dependent apoptosis involves the permeabilization of mitochondrial membranes, which appears to mediate the release from the intermembrane space into the cytosol of apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF), Smac/ DIABLO, and endonuclease G [69, 70] . Cytochrome c, a soluble protein, normally resides between the inner and outer mitochondrial membrane and participates in oxidative phosphorylation; once released, it acts to induce the formation of the apoptosome, composed of cytochrome c, Apaf-1, dATP and procaspases 9 to activate caspases and subsequently the execution of programmed cell death [69, 70] . How cytochrome c and other apoptogenic factors are released from mitochondria is not clear and proposed models are presented below.
VDAC and the PTP
There is substantial evidence connecting VDAC to apoptosis and suggesting that VDAC is a critical player in the release of apoptogenic proteins from mitochondria in mammalian cells. The diameter of the VDAC pore at its high conductance state is about 2.6-3.0 nm, sufficient to move nucleotides and small molecules, but insufficient to pass a folded protein like cytochrome c [71] . Accordingly, several hypotheses regarding the mechanism of mitochondriamediated apoptosis in which VDAC is involved have been proposed. One of the models proposes that VDAC is a component of the permeability transition pore (PTP) that is activated by pro-apoptotic stimuli [5, 70, 72] . Another model proposes that Bax interacts with VDAC, resulting in cytochrome c permeation through the OMM [73, 74] . A third model proposes that closure of the VDAC channel prevents the efficient exchange of ATP and ADP between the cytosol and mitochondrial matrix followed by swelling and rupture of the membranes [75] . A recent model proposes VDAC oligomerization as a process mediating release of proapoptotic proteins [24, 26] .
VDAC, The Mitochondrial Permeability Transition Pore (PTP) and Apoptosis
Mitochondria, following Ca 2+ accumulation, can undergo a sudden permeability increase to solutes (up to 1500 Da) [5, 72, 76, 77] . This permeability transition (PT) could also be caused by other factors, such as changes in the energetic balance of the mitochondria, anoxia, and radical oxygen species (ROS) (reviewed in [70, 78, 79] ). It has been suggested that Ca 2+ -dependent operation of the PT pore (PTP) is a key event committing the cell to an apoptotic fate [72, 77, 79, 80] . The PTP complex includes VDAC at the OMM, the adenine nucleotide translocase (ANT) in the IMM, and cyclophilin-D (CyP D) (located in the mitochondrial matrix). In addition, PTP can interact with the peripheral benzodiazepine receptor (in the OMM), creatine kinase (in the intermembrane space), and HK-I or II (tethered to VDAC on the cytosolic face of the OMM), as well as with Bax/Bcl-2 proteins (Fig. 5) [5, [79] [80] [81] . PTP is a regulated pore and is a large-conducting, voltage-dependent, non-selective channel with a pore diameter of about 3 nm, features that are compatible with those of VDAC [81] .
The VDAC-ANT Complex as a Permeability Transition Pore
Isolated VDAC and ANT complexes co-purify with other mitochondrial proteins such as HK [4] , benzodiazepine receptor [82] and creatine kinase [4, 5, 83] . Based on the separation and purification of the different complexes, two types of VDAC-ANT complexes could be defined: one complex where VDAC and ANT interact directly, thus providing VDAC with higher affinity for HK (Fig. 5A) , and a second complex where VDAC interacts indirectly with ANT through mitochondrial creatine kinase octamer [84, 85] . In this case, VDAC apparently exposes a different structural motif at the cytosolic side that has lower affinity for HK, so that HK activity is always absent in the complexes that contain creatine kinase [86] . VDAC-ANT complexes may also exist alone without any bound kinase (Fig 5AI & AII) , and VDAC may exist outside the contact sites as monomers or oligomers (( Fig. 5AI & AII) and [21] ).
The dissociation of the VDAC-ANT complex is also modulated by mitochondrial creatine kinase. Creatine kinase forms an octamer that can interact with both the inner and the outer mitochondrial membranes [87] . Creatine kinase octamer interaction with VDAC results in separation of the VDAC-ANT complex, thus acting as a lock between VDAC and ANT to prevent permeability transition.
VDAC as a Component of PTP
The evidence for VDAC being a component of PTP is supported by the following observations: (a) VDAC is enriched at contact sites between inner and outer mitochondrial membranes [88] . (b) PTP has properties (e.g., voltagedependence, pore size, selectivity, conductance, etc.) similar to those of VDAC [79, 89] . (c) VDAC was purified as a complex with ANT on the CyP-D column, and when this complex was reconstituted into liposomes, Ca 2+ induced the formation of a CsA sensitive pore [89] . (d) Several antiapoptotic proteins, such as members of the Bcl-2 family (Bcl-2, Bcl-xL) and gelsolin, close the VDAC channel [74, 90] , whereas some pro-apoptotic proteins of the Bcl-2 family (Bax, Bak, etc.) accelerate the opening of VDAC or interact with VDAC to form a channel through which cytochrome c can pass [73, 74] . Moreover, yeast cells (and their isolated mitochondria) knocked-out for VDAC1 fail to release cytochrome c induced by Bax or Bak, and this loss is restored by human VDAC1 [73, 74] . Bax also interacts with erythrocytesurface VDAC, and Bax-induced lysis of erythrocytes is VDAC dependent [91] . (e) NADH inhibits PTP [92, 93] and facilitates VDAC closure [94] . (f) Anti-VDAC antibodies prevent both Ca 2+ -induced and Bax-induced cytochrome c release and ∆Ψ loss in isolated mitochondria as well as apoptosis induction in cells [91] . (g) Recently, it was found that VDAC is permeable to Ca 2+ and possesses Ca 2+ -binding sites that may regulate PTP activity [95] . (h) VDAC was proposed to be a target of arsenic trioxide (As 2 O 3 ), which induces apoptosis and cytochrome c release in malignant cells [96] . (i) The HIV viral protein R (Vpr), a facultative inducer of apoptosis which can cause mitochondrial permeabilization, directly interacts with ANT and VDAC; yeast strains lacking these proteins are less susceptible to Vprinduced killing [97] . (j) Binding of HK-II to mitochondria via VDAC inhibits Bax-induced cytochrome c release and apoptosis, while overexpression of Bax detaches HK-II and induces mitochondrial dysfunction and cell death [98, 99] . (k) HK-I interacts with VDAC, induces its closure (Fig. 4D) , prevents PTP opening ( Fig. 3C) and, when over-expressed in U-937 cells, prevents staurosporine-induced cell death ( [100] & Fig. 4B ). (l) Ruthenium red (RuR) inhibits VDAC conductance ( Fig. 4C ) and prevents PTP opening ( [5, 7, 95] , Fig. 3A & B) . Thus, it seems to be well established that VDAC is a major component of PTP.
Two major models have been suggested for mitochondrial swelling during apoptosis. The first model postulates a defect in mitochondrial ATP/ADP exchange, possibly due to VDAC closure, leading to hyperpolarization of the IMM and subsequent osmotic matrix swelling [101] . According to the second model, the swelling is caused by the opening of PTP or the mitochondrial mega-channel (MMC) [81, 84, 102] , reviewed in [4, 70, 78, 79] .
Although the mechanism(s) responsible for PTP opening or assembly have not yet been resolved, a variety of agents have been found to promote or inhibit its activity, among which are Ca 2+ and inorganic Pi, various oxidizing agents, ANT and CyP-D ligands, proteins of the Bcl-2 family, hexokinase, glutamate, divalent cations, and nucleotides (reviewed in [5] ). Some of these various compounds and pro-teins have been shown to interact with VDAC and modify its activity.
Cytochrome c Release Pathway
Release of cytochrome c from mitochondria is considered to be a key initial step in the apoptotic process, although the precise mechanisms regulating cytochrome c release remain unknown. To date, all of the mitochondrial components known to translocate to the cytoplasm following an apoptotic stimulus reside in the mitochondrial intermembrane space. Therefore, only the OMM needs to be modified. Indeed, some models suggest that release exclusively involves an increase in OMM permeability due to the formation of a channel large enough to account for the release of proteins such as cytochrome c, while others consider release due to disruption of the OMM [24, 103, 104] . When considering models of protein release via PTP [70, 76, 77, 80, 104] , and more specifically via VDAC [2, 5, 24, 70, 79, 91, 104, 105] , the molecular sizes of the released proteins (12 to 100 kDa) and the VDAC pore diameter (~3 nm) make it difficult to imagine direct transport of these proteins through the VDAC pore. Accordingly, several possible mechanisms for the release of cytochrome c have been proposed. Among these models are: VDAC forms a nonspecific pore in the OMM or Bax and VDAC cooperate to form a novel, high-conductance channel in the OMM. Other suggestions include a Bax channel formed by its oligomerization and Bid formation of lipidic pores [106] . A. Ca 2+ -dependent mitochondrial swelling, monitored by the decrease in absorbance at 520 nm, was assayed in the absence (control, l) or upon addition at the time indicated by an arrow of 5 µM (w) or 10 µM (¡) of RuR. B. Rat liver mitochondria (0.5 mg/ml) were assayed for succinate-supported [ 45 
Ca
2+ ] accumulation in the absence (control, l) or the presence of 5 µM RuR (¡) added at the time indicated by an arrow as a function of time. C. Mitochondrial swelling assayed in the absence (control, l) and in the presences of HK-I [0.75 (¡) or 1.0 (w) U/ml]. D. Release of cytochrome c was assayed following incubation of mitochondria for 10 min in the absence or the presence of HK-I (1.0 U/ml) in the absence or the presence of 0.2 mM Ca 2+ and 5 mM succinate, conditions that inhibited or induced PTP opening, respectively. After centrifugation at 20, 000 x g, supernatants were assayed for cytochrome c release using anti-cytochrome c antibodies.
VDAC as a Constituent of the Apoptogenic Proteins Release Pathway
Studies using proteoliposomes and electrophysiology have revealed functional interactions between the VDAC and Bcl-2 family members [24, 73, 91, 105, 107, 108] . Electrophysiological studies of Bax and VDAC in planar lipid bilayers revealed that when combined, the single-channel conductance rises by factors of 4 and 10 over VDAC and Bax channels alone, respectively [107] , and VDAC-containing liposomes containing Bax or Bak become permeable to cytochrome c. Conversely, addition of Bcl-xL, but not Bcl-xL mutants, decreases VDAC permeability to cytochrome c. The involvement of the BH3 domain of Bax in the formation of the combined Bax/VDAC channel and of the BH4 domain of Bcl-xL in the inhibition of this channel activity was proposed [107] . Other studies demonstrated the release of cytochrome c via purified VDAC reconstituted into liposomes in which cytochrome c had been encapsulated [24, 105] . Our results show that VDAC can exist as oligomers, and that their formation can be induced and/or stabilized by cytochrome c. This leads us to hypothesize that tetrameric VDAC is the structure mediating the release of cytochrome c [24] . However, the molecular architecture of the cytochrome c-conducting channel formed by VDAC, alone or with Bax (Bak), is yet to be determined.
VDAC Oligomerization and Release of Cytochrome c
Both soluble, purified VDAC and membrane-embedded VDAC can assemble into dimers, trimers and tetramers as demonstrated by cross-linking with five cross-linking reagents bearing different spacer lengths (3-16 Å) and membrane permeability [24] . VDAC assembly into oligomers is a dynamic process as demonstrated by the FRET obtained between purified VDAC labeled with either FITC or EITC. Biochemical and electrophysiological evidence indicates that VDAC tends to form dimers or oligomers in yeast and in artificial bio-lipid membranes [21, 81] . Other studies using purified rat liver [24] , brain mitochondria [25] or recombinant human VDAC [26] , have reported the existence of VDAC dimers to tetramers (see section 1.1). The mechanisms of how cytochrome c and other apoptogenic factors are released from mitochondria remain elusive, and several possible mechanisms have been proposed (see sections 2.2 and 2.3). Possible involvement of VDAC oligomerization in the release of cytochrome c from mitochondria was recently suggested [24] . It was also demonstrated that VDAC oligomerization is encouraged in the presence of cytochrome c. In VDAC-reconstituted liposomes containing encapsulated cytochrome c, but not in VDAC liposomes free of cytochrome c, VDAC dimers, trimers and tetramers were observed even without chemical cross-linking [24] . Cytochrome c is attached to the IMM facing the inter-membranes space, and is present in loosely and tightly-bound pools attached to cardiolipin [109] . The signaling mechanisms responsible for cytochrome c translocation from the IMM prior to its release are not yet known. Dissociation of cytochrome c from its binding site can be induced by cardiolipin peroxidation [110, 111] or by Ca 2+ interaction with cardiolipin [112] . The dynamic equilibrium between VDAC monomeric and oligomeric states could be regulated not only by cytochrome c, but also by additional factors, such as Ca 2+ , oxidative stress or low ATP concentrations, or by interactions with other proteins known to act as modulators of cytochrome c release, such as hexokinase and Bcl-2 family members [5, 70, 72, 76, 77, 100, 113, 114] . The interaction of the Bcl-2 family members, proteins that act as pro-or anti-apoptotic proteins, with VDAC and the subsequent effect on the release of cytochrome c [2, 112, 115] can also be explained by a modulation of the VDAC oligomeric state. Indeed, it has recently been demonstrated that Bax increases the pore size of rat brain mitochondrial VDAC in the presence of tBid [116] .
Interestingly, in studies on the effect of the reagent As 2 O 3 on apoptosis, its apoptosis-inducing effect was attributed to an induction of homodimerization of VDAC molecules. This effect can be prevented by overexpression of the antiapoptotic protein Bcl-xL [117] . Based on these data and the finding that Bcl-xL interacts with VDAC via the putative loop region [117] , it has been proposed that Bcl-2/Bcl-xL may interact with VDAC to block its dimerization sterically [96] . This attractive, novel mechanism of dynamic VDAC oligomerization as mediator of cytochrome c release, and thus mitochondria-mediated apoptosis and its regulation by apoptotic proteins requires further investigation to explore in vivo the functional significance of VDAC oligomerization and its regulation by Bcl-2 family proteins.
VDAC Tetramers as a Site for Oligomerization of Associated Proteins
VDAC oligomerization has been suggested to play a role in the interactions between VDAC and associated proteins that serve as regulators of apoptosis [24] . Oligomerization of the pro-apoptotic protein Bax before [118] or during its binding to VDAC has been proposed [2] . HK-I binding to mitochondria and subsequent prevention of PTP opening shows a high degree of co-operativity [100, 119] , consistent with formation of HK tetramers during binding to mitochondrial VDAC [120] . In fact, Bax and HK-II compete for VDAC binding sites [99] . Mitochondrial creatine kinase interacts with VDAC exclusively in the octameric state, while the dimer has only weak affinity for VDAC [121, 122] . Thus, the fact that numerous VDAC-interacting proteins bind VDAC as oligomers lends support to VDAC itself existing in a high-order structure. The function of these VDAC oligomeric structures in the release of cytochrome c (Fig. 5) , although requiring further study, presents a new view for the mechanism for the release of apoptotic proteins and may facilitate a better understanding of mitochondria-mediated apoptosis and its regulation.
Analysis of VDAC Apoptotic Activity with Anti-VDAC Antibodies
Anti-VDAC antibodies have been used for analysis of VDAC function in various processes. Anti-VDAC1 antibodies generated by Shimizu et al. (Ab# 25) [91] were found to block VDAC activity. These anti-VDAC antibodies, when microinjected into cells, prevented Bax-induced cytochrome c release and apoptosis, but not Bid-induced apoptosis, indicating that VDAC is essential for Bax-induced, but not Bidinduced, apoptotic cell death. In addition, microinjection of these anti-VDAC antibodies significantly inhibits etoposide-, paclitaxel-, and staurosporine-induced apoptosis. In perme-abilized mammalian cells in which cytochrome c release and loss of ∆Ψ are induced by superoxide radicals, both cytochrome c release and loss of ∆Ψ are prevented in cells pretreated with the anti-VDAC antibody Ab#25 [105] .
Anti-VDAC antibodies also specifically and effectively prevent As 2 O 3 -induced cytochrome c release from isolated mitochondria [96] , and inhibit the apoptotic process induced by opening of plasma membrane VDAC [123] . Acute ethanol exposure induces oxidative stress and apoptosis in primary rat hepatocytes and this involves Bax translocation from the cytosol to mitochondria before the release of cytochrome c. Microinjection of anti-VDAC antibodies effectively prevents apoptosis and Bax-VDAC interactions induced by ethanol [124] . The inhibition of cytochrome c release, cell death and Bax-VDAC interaction by anti-VDAC antibodies indicates that VDAC has a central role in apoptosis.
REGULATION OF VDAC ASSOCIATED ACTIVITIES
The regulatory mechanisms controlling VDAC activity, and thus OMM permeability, are of critical importance for understanding mitochondrial function in life and death processes (reviewed in [5, 7] and summarized in Table 1 ). A number of substances have been shown to modulate VDAC channel activity, including small molecules (calcium, glutamate, reactive oxygen species), and proteins -most notably those of the Bcl-2 family and hexokinase.
Protein Modulators
It has been suggested that VDAC permeability, and thus OMM permeability, is regulated by associated protein(s). VDAC possesses binding sites for glycerol kinase [125] , HK-I and creatine kinase [85] , and forms complexes with various proteins, such as the dynein light chain, benzodi- (1)-CK refers to the octameric conformation of the mitochondrial isozyme.
(2) -Arsenic trioxide induces VDAC oligomerization.
azepine receptor, mtHSP70, ORDIC channel, and ANT (reviewed in [5] [6] [7] ). VDAC interacts with a specific unidentified modulator, possibly in the intermembrane space, which increases its voltage dependence and decreases its conductance [126, 127] . VDAC also interacts with apoptosis regulating proteins, mainly members of the Bcl-2 family [91, 108, 128] , glyceraldehyde 3-phosphate dehydrogenase [7] and gelsolin [90] , which are considered to be pro-apoptotic proteins [129, 130] . Human VDAC1 shows strong affinities to the different kinases [39] .
VDAC Interaction with Bcl-2 Family Members
VDAC interacts with apoptosis-regulating proteins such as Bax/Bak (pro-apoptotic) and Bcl-xL (anti-apoptotic) [73, 74, 91, 108, 131, 132] . Tsujimoto and coworkers have reported direct interaction of VDAC with Bcl-2 family proteins like Bax, Bim and Bcl-xL in isolated mitochondria and in reconstituted membrane systems [73, 74, 91, 108] . The conductance of reconstituted VDAC is increased in the presence of Bax and this increase is blocked by Bcl-xL [73] . Bax and Bim interact with VDAC and lead to the release of cytochrome c, whereas Bcl-xL blocks this release [107, 108] . In addition, cytochrome c release induced by Bax and Bim is inhibited by anti-VDAC antibodies [91] . Further support for the involvement of VDAC in the Bax/Bak-induced release of cytochrome c comes from experiments with porin-less yeast cells. When VDAC1 is knocked out in yeast cells, neither yeast cells nor isolated yeast mitochondria show cytochrome c release induced by Bax or Bak, and this loss is restored by human VDAC1 [73, 133] . On the other hand, it has also been shown that Bid, but not Bax, regulates VDAC channels [132] . It is possible, however, that the pro-apoptotic proteins (e.g., Bax, Bak) do not modulate VDAC activity but rather, together with VDAC, form a channel with novel properties that permits cytochrome c release, while the anti-apoptotic protein Bcl-xL or its BH4 domain produce inhibition (reviewed in [5] [6] [7] ).
It has also been suggested that VDAC interacts with both Bax and Bcl-xL to form a tertiary complex, and that the function of VDAC in mediating cytochrome c release could depend on the ratio between Bax and Bcl-xL [117] . Another pro-apoptotic Bcl-2 family protein, truncated C terminus Bid (tcBid) has also been suggested to interact with VDAC to form novel pores in the OMM [106] . It has been reported that tBid/Bax oligomers may themselves form channels in the outer membrane or they could interact with other OMM proteins like VDAC to induce cytochrome c release [134] . In contrast, it has recently been reported that the properties of VDAC channels isolated from mammalian mitochondria are unaffected by addition of Bax in the planar lipid bilayer and that Bax does not induce cytochrome c release by acting on VDAC [132] . Results showing that Bax increases the pore size of rat brain mitochondrial VDAC in the presence of tBid were also reported [116] . It has been found that HK and Bax compete for the same binding site [99] . VDAC and ANT were co-immunoprecipitated with anti-Bax antibodies in extracts from cardiomyocytes [135] . These results indicate that the regulation of VDAC by Bcl-2 family proteins can be a crucial factor in inducing release of apoptogenic proteins from mitochondria.
Hexokinase (HK) Interaction with Mitochondrial VDAC, Apoptosis and Cancer
In mammalian cells, several isoforms of hexokinase (HK) are present. Hexokinase isoform I (HK-I) and isoform II (HK-II) are primarily mitochondrial [136] . HK-I and HK-II dock on to the cytosolic surface of the OMM mainly by binding to VDAC [83] . It has been proposed that binding of HK to mitochondria allows a continuous ATP flux, providing energy for phosphorylation of glucose, and thus an increased glycolytic rate [137] . The binding of HK to VDAC is very specific since exchanging glutamate 72 for glutamine in VDAC completely abolishes hexokinase binding [52] .
Cancer cells are characterized by a high rate of glycolysis which serves as their primary energy generating pathway [138] . The molecular basis of this high rate of glycolysis involves a number of genetic and biochemical events, including overexpression of mitochondrial-bound isoforms HK-I and HK-II [138] . It has been shown that cancer cells possess high levels of HK activity and that drugs that detach HK from mitochondrial membranes decrease cell viability [139] .
Recently [100] , we demonstrated that HK-I directly binds to a bilayer-reconstituted VDAC and induces closure of its channel that is reversed by glucose-6-phosphate. Furthermore, HK-I interacts with isolated mitochondria and prevents PTP opening and cytochrome c release, thereby, blocking the gateway to apoptosis. Indeed, overexpression of HK-I in the tumor-derived cell line U-973 or vascular smooth muscle cells, suppresses staurosporine-induced apoptotic cell death ([100] see also Fig. 4B) . A decrease in apoptotic cell death and increase in cell proliferation have also been reported to be induced by HK-II expression in NIH-3T3 [140] and Rat 1a cell lines [141] . In addition, binding of HK-II to mitochondria inhibits Bax-induced cytochrome c release and apoptosis [99] . These results suggest that HK-I, by interacting with VDAC, prevents key events in mitochondria-mediated apoptosis.
Overexpression of mitochondrial bound HK reduces apoptosis induced by different stimuli, presumably by modifying VDAC function [99, 140] . In isolated mitochondria, HK-II interferes with Bax-VDAC interaction thereby inhibiting cytochrome c release [99] .
HK Binding to VDAC Reflects VDAC Sensing of Inner Membrane Functions at the Contact Site
Immuno-electron microscopy and binding studies have demonstrated that HK binds with higher capacity to VDAC at the contact sites compared to VDAC beyond contacts [142] . A sigmoidal type of HK binding to mitochondria was observed only when contact sites are present [119] , suggesting cooperative binding of HK tetramers to VDAC in the contact site area [120] . Analysis of different epitopes at the surface of bound HK using specific monoclonal antibodies indicates a variation of the bound HK structure that correlates with functional changes in oxidative phosphorylation in the inner membrane [143] . This direct reflection of inner membrane functions at the mitochondrial periphery can be explained by interaction between VDAC in the outer and ANT in the inner mitochondrial membranes [84, 86, 144] . In a recent application, HK was used to indicate structural changes of VDAC correlated to the functional state of ANT [145] . Isolating mitochondria contact sites, HK activity was found to decrease when ANT was shifted to the mconformation by bongkrecic acid, whereas HK activity was increased after induction of the c-conformation by atractyloside [145] . Based on the evidence of different affinity and capacity of HK binding inside and beyond the contact sites, we can define a tense and relaxed state of VDAC in analogy to the regulation of allosteric enzymes. The tense state of VDAC could be the low conductance, cationically selective pore in a complex with ANT (Fig. 5AI) , whereas the relaxed state of VDAC would be a monomeric form characterized by high conductance and anion selectivity (Fig. 5AI). 
Peripheral Benzodiazepine Receptor (PBR) and VDAC
The peripheral benzodiazepine receptor (PBR) is an evolutionarily conserved protein complex that binds benzodiazepines such as RO5-4864 and isoquinoline carboxamide derivatives such as PK11195 [146] . PBR is widely distributed throughout the body and has been associated with numerous biological functions in the regulation of cell proliferation, stimulation of steroidogenesis, immunomodulation, porphyrin transport, heme biosynthesis, anion transport and regulation of mitochondrial functions [147] . It has been suggested that PBR is a critical component of PTP and, as such, is involved in the regulation of apoptosis. This receptor includes a Mr 18, 000 isoquinoline-binding subunit predominantly located at the surface of the mitochondria where it is proposed to physically associate with VDAC-ANT [148] . In attempts to purify PBR as a native complex, a fraction consisting of three proteins was isolated from rat kidney mitochondrial membranes, containing isoquinoline binding protein (pk-18), VDAC and ANT. However, in those fractions, the stoichiometry shows that VDAC and ANT were much more prominent than pk-18. PBR is reported to be functionally associated with VDAC, ANT and an unknown 10-kDa protein [149] .
Gelsolin Interaction with VDAC and Pro/AntiApoptotic Activities
Gelsolin, a Ca 2+ -dependent actin-regulatory protein [150] , is suggested to be involved in the regulation of apoptosis and to possess tumor suppressor functions [151] . Overexpression of gelsolin inhibits the loss of ∆Ψm, and inhibits cytochrome c release from mitochondria. Interestingly, the apoptotic effects of gelsolin are species dependent: human gelsolin (hGsn) has anti-apoptotic activity, whereas mouse gelsolin (mGsn) exerts either pro-apoptotic or anti-apoptotic activity in different cell types. Endogenous and overexpressed hGsn have anti-apoptotic activity including preventing cytochrome c release that depends on the C-terminal half of hGsn. hGsn and its C-terminal half inhibit the activity of VDAC in liposomes through direct binding in a Ca 2+ -dependent manner [90] . These results suggest that hGsn inhibits apoptosis by blocking mitochondrial VDAC activity.
Non-Protein Physiological Modulators
VDAC permeability, and thus mitochondrial permeability, is regulated not only by associated protein(s), but also by various ligands. Accumulated evidence suggests that VDAC possesses regulatory binding sites for Ca 2+ [95] , NADH [94, 152] , nucleotides [32, 153] and glutamate [154, 155] (reviewed in [5] ). The localization of the binding sites of these ligands as well as their physiological function awaits further studies.
Calcium Ions, Apoptosis, Mitochondria and VDAC
Ca
2+ ions are very important regulators at the molecular, cellular and whole organism levels. Cellular Ca 2+ signals are crucial in the control of most physiological processes, cell injury and programmed cell death through the regulation of a number of Ca 2+ -dependent enzymes such as phospholipases, proteases, and nucleases [156] . Changes in intracellular Ca 2+ concentration not only stimulate a number of intercellular events, but can also trigger cell death pathways, including apoptosis [157] . Mitochondria, along with the endoplasmic reticulum, play pivotal roles in regulating intracellular Ca 2+ concentration. Mitochondria not only play an important role in Ca 2+ homeostasis, but interplay between mitochondrial function and cellular Ca 2+ signaling exists [158, 159] . Increased intracellular Ca 2+ concentration acts as an important mediator of apoptosis in a variety of cells [160] . However, the precise mechanism by which intracellular Ca 2+ mediates apoptosis is not known. Mitochondria are endowed with multiple Ca 2+ transport mechanisms by which they take up and release Ca 2+ across their inner membrane [5, [161] [162] [163] . In isolated mitochondria, Ca 2+ induces PTP opening and release of cytochrome c [70, 72, 76, 80, 157] . Currently, the mitochondrial target of Ca 2+ activation of cytochrome c release has not yet been identified.
VDAC Interaction with Ca 2+
VDAC, as the OMM channel, must be involved in Ca 2+ transport into and out of the mitochondria. Indeed, VDAC is highly permeable to Ca 2+ and possesses Ca 2+ binding sites [95] . Several lines of evidence suggest that VDAC possesses divalent cation-binding site(s) (for review see [72] ). The evidence includes: (1) La 3+ and Tb 3+ , which are known to bind to Ca 2+ -binding proteins [164] , induce channel closure when assayed on VDAC reconstituted into a PLB [95] . (2) RuR [95] , and ruthenium amine binuclear complex (Ru360) [165] , known to specifically interact with several Ca 2+ -binding proteins [95, 166] , induce VDAC channel closure in a time-dependent manner, and stabilize the channel in a completely closed state. The inhibitory effect of RuR is prevented in the presence of CaCl 2 , but is re-established by chelating Ca 2+ with EGTA, suggesting that RuR interacts with a Ca 2+ -binding site in VDAC [95] . (3) As shown for other Ca 2+ -binding proteins [167] , there is a Ca 2+ -induced shift in VDAC electrophoretic mobility [95] . (4) The enhanced fluorescence of Tb 3+ in the presence of VDAC suggests that it interacts with a specific site on VDAC [95] . (5) Dicyclohexylcarbodiimide (DCCD), which reacts specifically with carboxyl groups (for review, see [168] ) has been shown to specifically label VDAC [83, [169] [170] [171] and to inhibit its channel activity [170, 171] . It is possible that DCCD modifies VDAC channel activity by interacting with a carboxyl group located in the Ca 2+ -binding sites. These findings and those presented in the next section (2.2.1) strongly support the suggestion that Ca 2+ -binding sites are present in VDAC and have regulatory functions. [5, 95, 166, [172] [173] [174] . In several proteins, RuR competes for the calcium-binding site and so it is used as a probe for calcium binding [174, 175] . RuR has been shown to inhibit several mechanisms involved in intracellular Ca 2+ regulation, including the mitochondrial uniporter and the "rapid mode" system [176] , sarcoplasmic reticulum (SR) Ca 2+ -ATPase activity [173] , Ca 2+ release and ryanodine binding by the Ca 2+ -release channel/ryanodine receptor [172] , and the binding of Ca 2+ to calsequestrin [166] and to calmodulin [174] , as well as preventing brain tubulin polymerization [177] . RuR, the trivalent cation Ru360, a derivative of RuR [178] , and azido-ruthenium (AzRu) [179] interact with bilayer-reconstituted VDAC and induce its closure (see also Fig. 4C) . The channel activity of recombinant native mVDAC1 but not of E72Q-mVDAC1 is inhibited by RuR (Fig. 4C) and Ru360 [52] . RuR and Ru360 also inhibit the opening of PTP (see Fig. 3 ). RuR was shown to protect against cell death induced by different stimuli, including curcumin in U-937 cells [180] , ursolic acid in HL-60 cells [181] and microcystin in cultured rat hepatocytes [182] (see also below). The mechanism(s) underlying the protective action of RuR against apoptosis remains unknown. Such protection may result from RuR binding to intracellular organelles or proteins responsible for Ca 2+ buffering. However, the effect of RuR may result from its interaction with VDAC1, inducing its closure [95] . The inability of RuR and Ru360 to protect against apoptotic cell death in cells expressing E72Q-VDAC ( [52] & Fig. 4) suggests that the reagents exert their protective effect on the apoptotic process by direct interaction with VDAC and that VDAC plays a central role in apoptotic cell death.
Ruthenium-Containing Compounds Interact with VDAC and Modify its Activities
Possible Localization of VDAC Divalent CationBinding Sites
As presented above, VDAC possesses yet unidentified Ca 2+ -binding site(s). The primary amino acid sequence of VDAC1 contains no features of EF-hand structures that represent high-affinity Ca 2+ -binding sites. In proteins, ionophores and divalent chelating reagents (e.g. EGTA, EDTA), the ligation center for divalent cations binds through a carboxylate group or neutral oxygen center. Accordingly, aspartateglutamate rich regions may form potential low-affinity Ca 2+ binding sites. To identify possible Ca 2+ binding sites in VDAC and their involvement in VDAC regulation of cell life and death, recombinant murine VDAC1 was modified by site-directed mutagenesis, and expressed in Saccharomyces cerevisiae and U-937 cells. De Pinto et al. [169] identified Glu72 as the DCCD-binding amino acid in VDAC. Indeed, replacement of Glu72 by glutamine eliminated RuR and Ru360 inhibition of VDAC channel activity and their protection against cell death ([52] & Fig. 4) . These results suggest that it is most likely that Glu72 participates in a Ca 2+ -binding site(s) or is required for stabilizing VDAC in a conformation recognized by RuR, Ru360 and HK-1. Since RuR, as a hexavalent reagent, is expected to bind to more than one negatively charged group [183] , in addition to Glu72, other negatively charged amino acids may be involved in RuR interaction with VDAC. Further studies are required for identifying, localizing, and establishing the function of the Ca 2+ -binding sites in VDAC.
Nucleotide Permeability Through VDAC and Regulation of VDAC Activity
VDAC provides the pathway for ATP/ADP and other nucleotides into and out of the mitochondria, as well as possessing nucleotide-binding sites (NBS). In isolated mitochondria, treatments that induce VDAC closure inhibit adenine nucleotide fluxes and mitochondrial function [31, 184] , suggesting that VDAC mediates and controls adenine nucleotide flux. Indeed, VDAC was shown to transport ATP when reconstituted into both PLB [32, 33] and liposomes [185] , and the flux measurements suggest that VDAC is sufficient to mediate ATP flux across the OMM [32] . VDAC was also found to be the major pathway for NADH flux across the OMM in S. cerevisiae [42] [43] [44] 152] , and thus can regulate mitochondrial functions such as respiration.
Several different studies suggest that VDAC possesses NBS [152, 186] . "Current noise spectral analysis" was used to investigate the effect of ATP and other nucleotides on the conductance of the VDAC channel [153, 187] and the results suggest that ATP sterically blocks the channel, probably due to the presence of a binding site [187] . NADH was shown to increase VDAC voltage dependence and the gating charge of both human and two fungal VDACs (N. crassa and S. cerevisiae) [94] , as well as to reduce OMM permeability to ADP (by a factor of 6) [152] . Purified VDAC was bound to reactive red-120-agarose column, (shown to bind nucleotide binding proteins [188] ) and eluted with ATP [189] . Similarly, VDAC binds to ATP-agarose and is eluted with ATP [186] .
Based on the interaction of VDAC with NADH, and similarities to known ATP-binding sequences, Zizi et al. [94] suggested two possible NBS. The first is a high-affinity, glycine-rich site, located at the C-terminal of VDAC, which seems to be conserved among VDAC molecules from various species (e.g., N. crassa, S. cerevisiae, rat and human). This site is homologous to the nucleotide-binding regions of ANT and reminiscent of NBS in ATP-binding enzymes [190, 191] . It should be noted that although this sequence is not identical to the classical dinucleotide binding sequence, it is still well within acceptable variation. Based on 32 P-ATP labeling of intact VDAC and of a VDAC fragment containing a postulated nucleotide-binding sequence (GYGFG), the NBS of VDAC has been proposed to be localized to the Nterminal portion of the protein [186] . This site is similar to the nucleotide binding Walker motif A [190, 192] , but its sequence, TKGXGXG, is inverted compared with the motif, i.e., G(X/G)XGXGKT. [94] . Since this site is located only at the N-terminal of human VDAC1 while human and N. crassa, and S. cerevisia bind NADH, it is unlikely to be involved in NADH binding.
To identify the ATP binding sites in the VDAC molecule, the protein was labeled with the photoreactive ATP analog benzoyl-benzoyl ATP ([α−
32 P]BzATP) [189] . [α-32 P]BzATP binds to purified VDAC at two or more binding sites with apparent high-and low-affinity binding compo-nents. The regulatory functions of these NBS of VDAC require further study.
Reactive Oxygen Species (ROS) and VDAC
Free radicals are potentially dangerous by-products of cellular metabolism, which have direct effects on cell growth and development and cell survival, and play a significant role in the pathogenesis of atherosclerosis, cancer, aging and several other conditions, including inflammatory diseases [193] [194] [195] . Free radicals are generated by aerobic organisms during the electron transport coupled to ATP production. Due to the leakage of electrons from mitochondria, reactive oxygen species, superoxide anion (O 2 -• ) and hydroxyl (OH • ) radicals, are generated. The electron transfer chain of mitochondria is a well documented source of H 2 O 2 , and mitochondria contribute 20-30% of the cytosolic steady-state concentration of H 2 O 2 [196] . It has been suggested that VDAC allows the movement of O 2 -• from the intermembrane space to the cytoplasmic surface of the OMM [197] . This suggestion is based on the finding that VDAC inhibitors DIDS and dextran sulfate inhibit O 2 -• production from mitochondria (in a voltage-dependent manner). O 2 -• evoked release of cytochrome c in VDAC-reconstituted liposomes and apoptosis are proposed to occur via VDAC-dependent permeabilization of the OMM, without damage to the IMM, since DIDS or antibodies that block VDAC prevent these effects [105] . A. U-937 human monocytic cells control or transfected with a plasmid encoding native or E72Q-mVDAC1 were incubated without (left lane) or with RuR (1 µM) for 18 hrs (right lane). RuR was added to the cells 56 hr after transfection, and 22 hr later cell viability was analyzed by Acridine Orange/Ethidium Bromide staining [52] (Bar = 12.5 µm). B. RuR or HK-I over-expression protects against apoptotic cell death induced by over-expression of native but not mutated E72Q-mVDAC1. For RuR experiments, VDAC1 or E72QVDAC1 expressing cells were incubated with RuR as described in A. For HK-I experiments, U-937 cells were transfected with pcDNA3.1-HisA-HK-I and grown in the presence of 400 µg/ml of neomycin. The stably HK-I expressing cells were then transfected with plasmid encoding mVDAC1 or E72Q-mVDAC1 and continue to grow in the presence of neomycin (400 µg/ml). The viability of the double-transfected cells was analyzed after 76 hr. In each independent experiment, approximately 200 cells were counted for each treatment, in which early and late apoptotic cells were also counted. Quantitative analysis of apoptosis in the different cells was performed by ANOVA and t test; p < 0.001 (***) was considered statistically significant. Data shown the mean ± S.E.M. (n=4). C. Currents through bilayer-reconstituted VDAC1 or E72Q-mVDAC1 in response to a voltage step from 0 to -10 mV were recorded before and 15 min after the addition of 50 µM ruthenium red (RuR). (D) Currents through VDAC1 or E72Q-mVDAC1 in response to a voltage step from 0 to -10 mV were recorded before and 5 min after the addition of HK-I purified from rat brain (25 mU).
Cholesterol and Cardiolipin Influence on VDAC Structure/Function
Sterols have been found in purified mitochondrial VDAC, such as ergosterol in N. crassa [198] and cholesterol in VDAC from bovine heart [199] . Sterols are essential for proper insertion of VDAC into bilayer membranes, and cholesterol increases VDAC conductance [200] . It was postulated that sterols may increase the hydrophobicity of the surface of the VDAC β-barrel structure exposed to the phospholipid matrix of the membrane. The OMM contains 10% clustered cholesterol, while almost none is found in the IMM [201] . The localization of VDAC inside or outside the cholesterol-containing lipid raft-like areas might explain the observed varying properties and structure of VDAC in different protein complexes. Interestingly, in certain tumor cells, a 3-fold higher cholesterol concentration was found and contact sites were absent, suggesting that VDAC-ANT complexes may also be missing [202] , and this may explain suppression of apoptosis in tumor cells.
Cardiolipin is a specific component of the IMM where it is tightly associated with several inner membrane proteins, controlling their activities and is important in apoptosis [203] . VDAC forms contact sites with ANT that contain tightly bound cardiolipin [204] , and Ca 2+ affects cardiolipin bound to ANT, thus affecting the interaction of VDAC with ANT. Mitochondrial creatine kinase is attached to cardiolipin in the IMM and generates contact sites [205] . As cytochrome c displays high affinity for cardiolipin as well, it is also concentrated in the contact sites [145] . It has been observed that cardiolipin is required for targeting tBid to mitochondria [206] , where it appears to interact especially in the contact sites [207] . The affinity of cytochrome c to cardiolipin is decreased in the presence of Ca 2+ [208] . The dissociation of cytochrome c from the anionic cardiolipin is a prerequisite step for its release and could be induced by cardiolipin peroxidation [103, 104, 109, 209] , by Ca 2+ interaction with cardiolipin [2] , or by tBid that mobilizes cytochrome c to the mitochondrial intermembranous space to facilitate its release [210] . It appears that cardiolipin might play an important role in apoptosis regulation.
Non-Physiological Reagents that Interact with VDAC
VDAC closure has been induced by various reagents, among which are Koenig's polyanion [211, 212] , RuR, DCCD, and 4, 4'-diisothiocyanostilbene-2, 2'-disulfonic acid (DIDS) (reviewed in [7] ). Other reagents have also been reported to interact with VDAC and to modify its activity. Inhibition of PTP opening, release of cytochrome c or apoptotic cell death by these reagents is often related to the interaction of the reagent with VDAC.
Koenig's Polyanion
VDAC closure can be induced by Koenig's polyanion [211, 212] . In isolated mitochondria, enzymes in the intermembrane space, such as adenylate kinase, have no access to external adenine nucleotides in the presence of Köenig's polyanion [213] , which induces the low conductance state of VDAC [28] . Koenig's polyanion is able to block cytochrome c transit through the liposomal membrane, suggesting that VDAC forms at least part of the functional pore [214] . On the other hand, Koenig's polyanion was also shown to enhance swelling and amplify cytochrome c release from CNS mitochondria [215] .
DIDS Modification of VDAC and Inhibition of Apoptosis
DIDS (4, 4'-diisothiocyanostilbene-2, 2'-disulfonic acid) has been shown to decrease the conductance of VDAC reconstituted into a planar lipid bilayer [171, 216] . DIDS modifies reactive lysine residues in proteins and is known to affect the activity of a number of transporters, including chloride channels. Thus, while it is not specific to VDAC, it has been considered to be a chemical blocker of VDAC. It thus should be used with caution. DIDS was shown to inhibit the transport of ATP into synaptosomes and SR, an activity that has been proposed to be mediated by VDAC [170, 171] .
DIDS has been used to investigate the role of VDAC in cellular processes. DIDS inhibits superoxide-induced release of cytochrome c and apoptosis in a hepatocyte cell line [105] , and blocks cytochrome c release and caspase processing in dexamethasone-treated thymocytes [217] . It has also been shown that DIDS can block apoptosis triggered by overexpression of rice VDAC in mammalian cells [218] . DIDS inhibits O 2 production from mitochondria in a voltagedependent manner, and this was interpreted as an indication that O 2 exits mitochondria via VDAC channels [197] .
Arsenic Trioxide [As 2 O 3 (ATO)] Induces Apoptosis and VDAC Dimerization
Arsenic, a natural substance that has been used as a drug for over 2000 years, has been brought back into use because of its remarkable therapeutic efficacy in patients with acute promyelocytic leukemia. In vitro and in vivo studies demonstrate that arsenic exerts a broad spectrum of anti-cancer effects by induction of apoptosis, inhibition of cell proliferation, anti-angiogenesis and possible immunomodulation [219] . Arsenic exerts a dose-dependent dual effect: it causes differentiation at low concentrations and apoptosis at relatively high concentrations. Arsenic-induced apoptosis occurs via a variety of mechanisms including direct effects on mitochondria. Arsenic induces a loss of inner mitochondrial transmembrane potential (∆ψ ), opens PTP, releases cytochrome c and apoptotic proteins into the cytosol, and causes caspase activation [96, 220] .
Based on the following, VDAC has been identified as a biological target of As 2 O 3 responsible for eliciting cytochrome c release: (a) The anti-VDAC antibody (Ab#25) specifically and effectively prevents As 2 O 3 -induced cytochrome c release from isolated mitochondria [96] . (b) Proteoliposome experiments show that VDAC is necessary and sufficient to mediate As 2 O 3 -induced cytochrome c release [96] . (c) Overexpression of Bcl-2 attenuates or delays apoptosis, cytochrome c release, and ∆Ψ reduction induced by As 2 O 3 in IM-9 cells, with Bcl-xL potently inhibiting As 2 O 3 -induced cytochrome c release from isolated mitochondria [96] . (d) As 2 O 3 reduces mitochondria membrane potential and cytochrome c release only in the VDAC-expressing, but not in the VDAC-deficient yeast strain [220] . (e) As 2 O 3 induces increased expression and homodimerization of VDAC in IM-9 cells, but not in Bcl-2 overexpressing cells. It was suggested, therefore, that VDAC homodimerization could potentially determine its gating capacity to cytochrome c, and Bcl-2 blockage of VDAC homodimerization represents a novel mechanism for its inhibition of apoptosis [96] . As 2 O 3 was found to up regulate the expression levels of VDAC [96] . This suggests that VDAC could potentially serve as a biological stress sensor for As 2 O 3 , either directly or indirectly. 
Aminoketone Derivatives
A number of aminoketone derivatives, such as Ro 68-3400, represent a class of compounds that inhibit PTP with low micromolar affinity. Labeling experiments using [ 3 H]Ro 68-3400 identified VDAC1 as a major molecular target of Ro 68-3400 in mitochondria [221] .
VDAC OVEREXPRESSION AND CELL DEATH
VDAC Over-Expression Induces Cell Death
As presented in previous sections, VDAC is not only a major OMM transporter, but plays an important role in apoptosis by participating in the release of intermembrane space proteins. To explore its function in apoptosis, human, murine, yeast and rice VDAC1 were expressed in different cells. Surprisingly, VDAC overexpression induces apoptotic cell death regardless of the cells used or VDAC1 sources, suggesting that VDAC is a conserved mitochondrial element of the death machinery [52, [180] [181] [182] 218] . Overexpression of murine or rat VDAC1 or VDAC1-GFP or E72Q-mVDAC1 in U-937 cells results in cell death (70 to 85%), characterized by nuclear fragmentation ( [52] and Fig. 4) . Similar results were obtained upon overexpression of rice VDAC in the Jurkat T-cell line [218] . This cell death was blocked by Bcl 2 or DIDS, also shown to inhibit VDAC channel activity [171] . Taken together, these results indicate that the cellular expression level of VDAC may be a crucial factor in the process of mitochondria-mediated apoptosis.
The question, however, is how does enhanced VDAC expression lead to cell death? It is possible that increased VDAC levels produce a significant increase in the leak of the OMM and this, in turn, decreases cell viability. Since RuR prevents cell death induced by VDAC overexpression, it seems that it is not an increase in the total amount of VDAC, but rather an increase in its functionality that is responsible for the apoptotic cell death [52] . Moreover, cells overexpressing HK-I, which reduces VDAC channel conductance, are resistant to cell death induced by VDAC overexpression [52] . These finding suggest that a functional VDAC is required for triggering cell death, yet the mechanism underlying cell death induced by VDAC overexpression is not clear.
As proposed above, a dynamic VDAC oligomerization is involved in the release of cytochrome c from mitochondria [24] . As such, VDAC overexpression would encourage VDAC oligomerization, and thus allow for release of proapoptotic proteins from the mitochondrial intermembrane space. Another possible mechanism for VDAC overexpression inducing cell death is via its interaction with ANT at the contact sites. An increase in expressed VDAC would increase VDAC-ANT complexes, proposed to be the target of pro-apoptotic proteins, while co-expressed HK-I would shield against this interaction, as has indeed been found [52] . In certain tumor cells, contact sites are absent, suggesting that VDAC-ANT complexes are also missing [202] and this may explain suppression of apoptosis in tumor cells. Support for involvement of VDAC oligomerization in apoptosis is presented in the studies that show that As 2 O 3 induces apoptosis and VDAC dimerization, which are prevented by overexpression of the anti-apoptotic protein Bcl-xL (see also above and [96] ).
It is known that radiation can also induce the upregulation of VDAC in LYas cells [222] , and increased expression of VDAC is correlated with uterine epithelial apoptosis after estrogen deprivation [223] .
Recently, electrophysiological and immunocytochemical studies demonstrated that opening of VDAC in the plasma membrane of neurons precedes caspase activation in neuronal apoptosis induced by toxic stimili. The apoptotic process is inhibited by anti-VDAC antibodies [123] .
The relationship between apoptosis induced by VDAC overexpression and VDAC oligomerization requires additional study, including direct monitoring of the oligomerization process in live cells, both in control cells and cells overexpressing VDAC.
RuR Inhibition of Apoptotic Cell Death Induced by Different Inducers
RuR was shown to inhibit cytochrome c release, activation of caspase 3 and curcumin-induced apoptosis in the U-937 cell line [180] . RuR also inhibits both ursolic acidinduced cell death in LH-60 cells [181] and microcystininduced cell death in cultured rat hepatocytes [182] . The mechanism by which RuR protects against cell death has not yet been established. However, as presented above, it is mediated via interaction with VDAC and inhibition of its activity [52] .
Curcumin Induces Apoptosis
Curcumin, a natural, biologically active compound extracted from rhizomes of Curcuma species, has been shown to possess potent anti-inflammatory, anti-tumor, and antioxidative properties [224] . Curcumin initiates apoptosis in U937 cells and induces translocation of cytochrome c from the mitochondria to the cytosol; both are inhibited by RuR [180] . The inhibition by RuR was interpreted by the authors as indicating that curcumin-induced apoptosis in U937 cells is mediated by an intracellular Ca 2+ signaling pathway and evidence points to the uniporter as the target.
Ursolic Acid Induces Apoptosis
Ursolic acid (UA), a pentacyclic triterpene acid, has been isolated from many kinds of medicinal plants, such as Eriobotrya japonica and Rosmarinus, and has been reported to produce anti-tumor activities [225] . UA induces decreased cell viability and apoptosis and these are inhibited by RuR. It has been suggested that the apoptosis-inducing activity of UA may be mediated by intracellular Ca 2+ release, but other possible mechanisms have not been excluded [181] .
Microcystins Induce Apoptosis
Microcystins are cyclic heptapeptide toxins produced by cyanobacteria (blue-green algae) and found to induce apoptosis in a variety of cell types [226] . Mitochondria have been found to be the major target in the microcystin-LR-induced apoptotic process [227] , and RuR was found to prevent the early mitochondrial Ca 2+ surge and attenuate the subsequent onset of PTP opening and cell death [182] .
Given the RuR-insensitive behavior of E72Q-mVDAC1, as reflected by the inability of RuR to inhibit channel activity in this mutant (Fig. 4C) , and to prevent cell death (Fig. 4A & B) , it appears that RuR protection against apoptosis induced by the various stimuli reported above is exerted through its direct interaction with VDAC.
Plant VDAC Induces Apoptosis
VDAC is present in plant cells such as potato [228] , wheat [229] and rice [218] .
Programmed cell death (PCD) is very much a part of plant life. Dying plant cells often share some features with apoptotic animal cells. These include appearance of cytochrome c in the cytosol [230, 231] , mitochondrial permeability transition [232] , activation of caspase-like proteases [233] , cellular and nuclear condensation, and internucleosomal fragmentation of nuclear DNA [234] . In heterologous expression studies, Bcl-2 family proteins appear to regulate plant PCD in a manner similar to mammalian cells [235, 236] . Mitochondrial proteins such as cytochrome c and PTP components, including VDAC and ANT, which play a key role in mammalian PCD, are conserved across plant and animal kingdoms. Interestingly, VDAC was found to be overexpressed during the hypersensitive response in plants [237] .
It has been demonstrated that overexpression of a rice VDAC (osVDAC4) in the Jurkat T-cell line induces apoptosis, which can be blocked by Bcl-2, DIDS and HK-II [218] . These findings suggest that VDAC is a conserved mitochondrial element of the death machinery in both plant and animal cells.
VDAC AND HUMAN DISEASE
There is a substantial amount of evidence connecting mitochondrial apoptosis to human disease. Mitochondriamediated apoptosis may play a crucial role in aging and in the pathophysiology of many important diseases, including heart attack and stroke, neurodegenerative disorders such as Parkinson disease, Alzheimer disease, ALS and mitochondrial encephalomyopathies and of course, cancer [238, 239] . Alterations in cell proliferation, cell death or both can lead to cancer development. Most treatments for cancer involve chemotherapy to induce the apoptotic process. Thus, apoptosis-related therapy is aimed at inducing cell death in unwanted cells (e.g. cancer), using apoptosis as a pruning tool. Indeed, induction of mitochondrial apoptosis is known to kill cells effectively, and one of the mechanisms by which chemotherapeutics destroy cancer cells is via inducing apoptosis [240] . In fact, recent studies have shown that a large number of anti-cancer drugs such as etoposide, doxorubicin [241] , lonidamine [242] , betulinic acid, arsenite, CD437, and several amphiphilic cationic α-helical peptides [243] exert their therapeutic action by inducing apoptosis in malignant cells [244] , mainly due to activation of the cytochrome c/caspase-9 pathway [245] . VDAC as regulator of mitochondrial function, the target of pro-and anti-apoptotic proteins and as a key protein in cytochrome c release is an appropriate target for therapeutic agents designed to modulate apoptosis.
A remarkable difference was observed in VDAC isoforms between tumor cells and normal tissues with respect to their transcript levels [49] . Cloning experiments on the three porin isoforms, VDAC1, VDAC2 and VDAC3 from the malignant tumor cell line AH130 clearly show that their primary structures are completely identical to those of the corresponding VDACs of normal liver cells. However, the transcript levels of the three VDAC isoforms in AH130 cells are significantly higher than those in normal liver [49] . Mitochondria from malignant tumor cell lines show a higher capability for hexokinase binding than those from normal liver [49] . These results suggest that the high HK-binding capability of malignant tumor cell mitochondria is due to a quantitative difference in binding sites.
In individual post-mortem brain regions of patients with Down syndrome, the level of VDAC1 is elevated whereas VDAC2 is normal, while in Alzheimer disease, VDAC1 and/or VDAC2 are significantly reduced or elevated in the various brain regions [246] . These observations may suggest derangement of VDAC function, reflecting impaired glucose, energy and intermediary metabolism as well as apoptotic mechanisms.
In a case report, a patient with deficient VDAC showed mitochondriopathy, and presented clinically with psychomotor retardation and minor dysmorphic features. Biochemical studies on the patient's muscle mitochondria showed impaired rates of pyruvate oxidation and ATP production and almost complete VDAC deficiency [247] .
VDAC concentration and isotype composition in the OMM are important for regulating the sensitivity to apoptotic signals. The general sensitivity of mitochondria for apoptotic signals is important in several human diseases. Some diseases, such as tumors, are caused by suppression of apoptosis, on the one hand, and other diseases, such as Alzheimer disease, are caused by increased apoptotic rate, on the other hand.
UNRAVELING VDAC-BASED BIOLOGIC THERAPY
Mounting evidence indicates that apoptosis is the predominant form of cell death triggered by anticancer drugs. Resistance to apoptosis can be acquired by cancer cells through a variety of strategies. In particular, altering a component of the apoptotic machinery has been shown to affect the dynamics of tumor progression, where inactivation of this machinery aids tumor development. The mechanisms that could confer drug resistance have been studied in a variety of ways [248] , and quenching of the mitochondrial apoptotic pathway has been suggested to occur for some drugs [249] . Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Recent studies suggest that Bcl-2 family members play a role in the mechanisms of resistance to anticancer drugs [250] . Since the Bcl2 family of proteins interact with VDAC (see above), as part of a central mechanism of amplification of the apoptotic signal, VDAC may be an appropriate target for therapeutic agents designed to modulate apoptosis. Moreover, chemoresistance may result from HK-I interaction with VDAC, preventing apoptosis [100] ; thus interfering with this interaction is a possible drug target.
Given that mitochondria can play a central role in the execution of apoptosis, with VDAC as a critical component, one can take advantage of this knowledge to generate practi-cal medical therapies. Both targeted overexpression and knock-down expression of VDAC in living cells open avenues for Cancer Biotherapy. In addition, it is possible to use targeted VDAC peptides that would minimize the selfdefense mechanisms of cancer cells that involve overexpression of anti-apoptotic proteins such as HK-I, thus increasing the efficacy of some of the chemotherapy drugs.
CONCLUDING REMARKS
Following identification of VDAC as the OMM channel, much has been learned about the protein's structure-function relationships, the biochemical and molecular bases of its activation and inactivation, and ways in which its activity is modulated in the cell. Biochemical and molecular approaches have revealed a remarkable diversity of regulatory mechanisms controlling VDAC function, ranging from Ca 2+ and adenine nucleotides to specific associated proteins. However, many interesting and important questions remain, and we now look forward to acquiring further information concerning the architecture of the channel pore, the location of modulator binding sites, and identification of the regions of the protein involved in channel gating. The identification of VDAC as playing a role in critical control points in the apoptotic pathway points to VDAC as being a rational target for the development of a new generation of therapeutics. suggestions. 
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